• 1
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 39093918.
  • 2
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphoma. Semin Oncol. 1993; 20: 7588.
  • 3
    Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005; 23: 50195026.
  • 4
    Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23: 84478452.
  • 5
    Liu Q, Cabanillas F, Hagemeister FB, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol. 2006; 24: 15821589.
  • 6
    Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non Hodgkin's lymphoma. Haematologica. 2001; 86: 951958.
  • 7
    Baldini L, Guffanti A, Gobbi P, et al. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. Cancer. 1997; 15: 12341240.
  • 8
    Lombardo M, Morabito F, Merli F, et al. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Studio Linfomi (GISL). Leuk Lymphoma. 2002; 43: 17951801.
  • 9
    Luisi D, Luminari S, Amatetti C, et al. BACOP/FND first-line treatment of follicular lymphoma. Multicentric study of GISL. Preliminary result. Ann Oncol. 2004; 15( Suppl 2): G17.
  • 10
    Luminari S, Lombarto M, Mammi C, et al. BACOP/FR front-line treatment of follicular lymphoma. A phase II study of the Gruppo Italiano Studio Linfomi (GISL). J Clin Oncol. 2006; 24: 18S. Abstract 7571.
  • 11
    Sacchi S, Tucci A, Merli F, et al. Efficacy controls and long-term follow-up of patients (pts) treated with FC plus rituximab for relapsed follicular NHL. Blood. 2003; 102. Abstract 4911.
  • 12
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 13
    Cox D. Regression models and life tables. J R Stat Soc B. 1972; 34: 187202.
  • 14
    Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma prognostic index. Blood. 2004; 104: 12581265.
  • 15
    Marcus ER, Solal-Celigny P, Imrie K et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma (NHL). Blood. 2006; 108. Abstract 481.
  • 16
    Buske C, Kneba M, Lengfelder E et al. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma — results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006; 108. Abstract 482.
  • 17
    Herold M, Antje Haas, Srock S, et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma — 4 year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39). Blood. 2006; 108. Abstract 484.
  • 18
    Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood. 2006; 108: 32953301.
  • 19
    Forstpointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclopshasphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of German-Low Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.